Gordon Brown

4.7k total citations · 2 hit papers
91 papers, 2.9k citations indexed

About

Gordon Brown is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Gordon Brown has authored 91 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Surgery, 48 papers in Pulmonary and Respiratory Medicine and 13 papers in Oncology. Recurrent topics in Gordon Brown's work include Bladder and Urothelial Cancer Treatments (30 papers), Prostate Cancer Treatment and Research (23 papers) and Urinary and Genital Oncology Studies (22 papers). Gordon Brown is often cited by papers focused on Bladder and Urothelial Cancer Treatments (30 papers), Prostate Cancer Treatment and Research (23 papers) and Urinary and Genital Oncology Studies (22 papers). Gordon Brown collaborates with scholars based in United States, Canada and United Kingdom. Gordon Brown's co-authors include Colin P. Dinney, Peter C. Black, Ashish M. Kamat, Mikkel Noerholm, Michael Donovan, Johan Skog, H. Barton Grossman, Wassim Kassouf, Surena F. Matin and James M. McKiernan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Gordon Brown

85 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy

2016 489 citations James M. McKiernan, Michael Donovan et al. profile →
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial Biopsy

2018 209 citations James M. McKiernan, Michael Donovan et al. profile →

Peers

Countries citing papers authored by Gordon Brown

Since Specialization

Citations

This map shows the geographic impact of Gordon Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Brown more than expected).

Fields of papers citing papers by Gordon Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Brown. The network helps show where Gordon Brown may publish in the future.

Co-authorship network of co-authors of Gordon Brown

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Brown. A scholar is included among the top collaborators of Gordon Brown based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Brown. Gordon Brown is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PD30-09 RESPONSE TO PRIMARY CHEMOABLATION WITH UGN-102 IN PATIENTS WITH NEW OR RECURRENT LG IR NMIBC: POST-HOC ANALYSIS OF THE ATLAS TRIAL 2024 ·The Journal of Urology ·Sandip M. Prasad, William C. Huang, Neal D. Shore, Brian Hu, Marc A. Bjurlin, Gordon Brown, (unknown), (unknown), Andrew Meads, Michael J. Louie, Mark Schoenberg	1
2	P2-08 LEGEND: A PHASE 1/2 STUDY OF EG-70 (DETALIMOGENE VORAPLASMID), A NOVEL, NON-VIRAL INTRAVESICAL GENE THERAPY FOR PATIENTS WITH BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU (CIS) 2024 ·The Journal of Urology ·(unknown), Shreyas Joshi, Matthew Bui, Rian J. Dickstein, (unknown), Yair Lotan, Scott Johnson, (unknown), Richard Bryce, (unknown), Joseph Zabell, Gary K. Steinberg, Gordon Brown	3
3	Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP) 2024 ·The Journal of Urology ·Neal D. Shore, Jason Hafron, Daniel R. Saltzstein, Gordon Brown, Laurence Belkoff, Pankaj Aggarwal, Jennifer Phillips, Amitabha Bhaumik, Tracy McGowan	2
4	Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ). 2024 ·Journal of Clinical Oncology ·Benjamin Lowentritt, (unknown), Dominic Pilon, (unknown), Erik Muser, Carmine Rossi, (unknown), (unknown), Jill Korsiak, Lorie Ellis, Patrick Lefèbvre, Gordon Brown	1
5	Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer 2022 ·Urology ·Benjamin Lowentritt, Gordon Brown, Dominic Pilon, Lorie Ellis, Guillaume Germain, Carmine Rossi, Patrick Lefèbvre, Kenneth Kernen, Paul Sieber, Neal D. Shore	4
6	Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases 2022 ·Targeted Oncology ·Gordon Brown, Laurence Belkoff, Jason Hafron, Daniel R. Saltzstein, (unknown), Amitabha Bhaumik, Jennifer L. Phillips, Tracy McGowan, Neal D. Shore	6
7	Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies 2021 ·Prostate Cancer and Prostatic Diseases ·(unknown), Gordon Brown, Alan W. Partin, Ballentine Carter, James M. McKiernan, Ronald Tutrone, Phillipp Torkler, Christian Fischer, Vasisht Tadigotla, Mikkel Noerholm, Michael Donovan, Johan Skog	66
8	Discrimination between attention deficit hyperactivity disorder and reactive attachment disorder in school aged children 2011 ·Research in Developmental Disabilities ·(unknown), Seonaid Anderson, (unknown), (unknown), David Young, Gordon Brown, Helen Minnis	26
9	The role of radical cystectomy in patients with clinical T4b bladder cancer 2010 ·Urologic Oncology Seminars and Original Investigations ·Peter C. Black, Colin P. Dinney, Gordon Brown, Wassim Kassouf, Arlene O. Siefker‐Radtke, Mark F. Munsell, H. Barton Grossman, Ashish M. Kamat	11
10	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma 2010 ·Cancer ·Surena F. Matin, Vitaly Margulis, Ashish M. Kamat, Christopher G. Wood, H. Barton Grossman, Gordon Brown, Colin P. Dinney, Randall E. Millikan, Arlene O. Siefker‐Radtke	154
11	Comparing Lymphadenectomy During Radical Nephroureterectomy: Open Versus Laparoscopic 2008 ·Urology ·J. Erik Busby, Gordon Brown, Surena F. Matin	26
12	Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer 2007 ·Expert Review of Anticancer Therapy ·Peter C. Black, Gordon Brown, Colin P. Dinney	10
13	Recurrence in Nonseminomatous Germ Cell Testis Tumor Patients with No Viable Tumor at Postchemotherapy Retroperitoneal Lymph Node Dissection 2007 ·Urology ·Philippe E. Spiess, Nizar M. Tannir, Gordon Brown, Ping Liu, Shi‐Ming Tu, James G. Evans, Louis L. Pisters	4
14	Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy 2007 ·Urology ·Gordon Brown, Surena F. Matin, J. Erik Busby, Colin P. Dinney, H. Barton Grossman, Curtis A. Pettaway, Mark F. Munsell, Ashish M. Kamat	81
15	Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen 2006 ·Cancer ·Philippe E. Spiess, Gordon Brown, Louis L. Pisters, Ping Liu, Shi‐Ming Tu, James G. Evans, Ashish M. Kamat, Peter McL. Black, Nizar M. Tannir	19
16	Neoadjuvant chemotherapy for bladder cancer 2006 ·World Journal of Urology ·Peter C. Black, Gordon Brown, H. Barton Grossman, Colin P. Dinney	29
17	Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: time to change the treatment paradigm? 2006 ·British Journal of Urology ·Gordon Brown, J. Erik Busby, Christopher G. Wood, Louis L. Pisters, Colin P. Dinney, David A. Swanson, H. Barton Grossman, Curtis A. Pettaway, Mark F. Munsell, Ashish M. Kamat, Surena F. Matin	100
18	Upper urinary tract tumors with nontransitional histology: A single-center experience 2006 ·Urology ·J. Erik Busby, Gordon Brown, Pheroze Tamboli, Ashish M. Kamat, Colin P. Dinney, H. Barton Grossman, Surena F. Matin	66
19	Should cystectomy only be performed at high-volume hospitals by high-volume surgeons? 2006 ·Current Opinion in Urology ·Peter C. Black, Gordon Brown, Colin P. Dinney	25
20	Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells 2005 ·Cancer Research ·Wassim Kassouf, Colin P. Dinney, Gordon Brown, David J. McConkey, Alan J. Diehl, Menashe Bar‐Eli, Liana Adam	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact